SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases

Inclusion Criteria: * Histology or cytology proven non-haematological cancer. * At least one metastasis should be localized in the infra-diaphragmatic soft tissue. * Eastern Cooperative Oncology Group (ECOG) scale of performance status ≤ 2. * ≥ 18 years old. * Life expectancy \> 6 months. * Target diameter (GTV) ≤ 5 cm. * Metastatic lesions must be visible, imaging defined targets and suitable for treatment with SABR. * In case of de novo OMD and oligometastatic recurrence a maximum of 5 targets (including the primary tumour) in a maximum of 3 organ sites are allowed. * In case of oligoprogressive disease (OPD) \* and induced OMD \*\* only 3 metastases (including the primary tumour) are allowed. * All metastatic sites are treated or planned for ablative therapy (including surgery). For OPD, only the sites in progression is required to fulfil this criterion. * A baseline scan within 28 days of inclusion (PET-CT or CT and MR scanning). * No curative intended treatment option available. * An ablative strategy should be deemed clinically relevant and it is at the discretion of the treating physician to decide. * Ability to understand and the willingness to sign a written informed consent document. * If the target is in the liver, a Child-Pugh Score A is required. Exclusion Criteria: * Patient cannot tolerate physical set up required for SABR. * Active bowel obstruction. * Uncontrolled intercurrent illness. * Medical contraindication to undergoing MR-imaging. * Pregnancy. * Patients with uncontrolled brain metastases. * Uncontrolled disease in respect to malignant pleural effusion, ascites, lymphangitic carcinomatosis, pleural carcinomatosis or peritoneal carcinomatosis. * If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints.